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FibrosisThe role of SPARC in the in vivo lung response to crocidolite asbestos was addressed by instillation of
crocidolite asbestos in a series of wild-type or SPARC-null mice. Animals were sacriﬁced at one week, one
month, and three months post-instillation to assess the impact of SPARC on multiple stages in the
development of ﬁbrosis. RNA was harvested from 10 animals/time point, pooled, and used to probe a mouse
array containing ∼10,000 probes. Gene expression data were analyzed for fold change, and for broader
functional group alterations. As expected, the one-week time point displayed alterations in genes involved in
immune recognition, energy utilization, and growth factor production. Later time points showed expression
alterations for genes involved in protein degradation, Wnt receptor signaling, membrane protein activity, and
transport. Molecules in the Wnt pathway have been implicated in bone growth, mediation of ﬁbroblast
activity, and have been directly linked to SPARC regulation.© 2009 Elsevier Inc. All rights reserved.Introduction
As a member of the matricellular class of secreted proteins,
SPARC (a secreted protein acidic and rich in cysteine) is involved
in the regulation of extracellular matrix (ECM) – cellular interac-
tions. SPARC has been localized to ﬁbroblasts found in idiopathic
pulmonary ﬁbrosis [1]. After embryogenesis, SPARC is most often
expressed in tissues undergoing remodeling [1,2]. SPARC is a
calcium-binding glycoprotein that interacts with many ECM
components including the ﬁbrillar collagens (types I, II, III, and
V) as well as type IV, thrombospondin1 (THBS1), vitronectin
(VTN), and ﬁbrinogen fragments D and E [3,4]. SPARC has been
shown to be a modulator of growth factors involved in ﬁbrosis and
has also been implicated in the development of cancers [5–7].
These characteristics may be linked to the activities of SPARC that
include stimulating the TGF-β signaling system, serving as a target
for and/or inducer of matrix metalloproteinases, and modulating
integrin-linked kinase activity [5,8,9]. It has also been shown that
SPARC interacts with the TGF-β-receptor complex to modulate
phosphorylation of Smad-2 (SMAD2), to affect the activity of JNK
(MAPK8), and to increase the expression of c-jun (Jun) [10]. More
recently, SPARC has been shown to interact with Stabilin-1
(STAB1), a scavenger receptor expressed on alternatively-activated
tissue macrophages and sinusoidal endothelial cells [11]. This.A. Putnam).
ll rights reserved.interaction regulates the extracellular concentration of SPARC and
thus potentially modulates ECM remodeling.
The 32 kDa SPARC protein is a member of a gene family with
structural similarities in the arrangements of the protein modules.
Other matricellular proteins in this family include SC1/Hevin
(SPARCL1), QR1 (NQO1), and Testican (SPOCK1) [12,13]. The
protein domains include a N-terminal acidic domain that contains
a low-afﬁnity calcium-binding domain and a transglutaminase
cross-linking site. This domain has been shown to inhibit cell
spreading. The central domain of the protein (aa 50–130) is similar
to follistatin (FST), and characteristically acts by inhibiting
proliferation and abrogating focal adhesions; however, release of
an internal peptide ([K]GHK) stimulates proliferation and angio-
genesis. The C-terminal domain (E–C) contains a high afﬁnity
calcium binding E–F hand domain that inhibits cell spreading and
proliferation, and is responsible for binding to cells and matrix
[3,12].
SPARC-null mice were developed independently by two groups
[14,15]. These mice are born phenotypically normal but develop
early cataracts, kinked tails, osteopenia and increased adipose
tissue. SPARC-null mice also demonstrate enhanced growth and
metastasis of implanted tumors, accelerated closure of cutaneous
wounds, collagen ﬁbrils with smaller and more regular diameters
and a diminished ability to encapsulate subcutaneously implanted
foreign bodies (see Framson and Sage [6] for review). It is
unknown how the lung will respond to asbestos exposures in
the absence of SPARC. Our investigations are designed to discover
Table 1
Number of gene transcripts altered N2 fold for each condition.
Mouse type Exposure length 1 wk 1 month 3 month
WT Up 59 31 44
Down 3 3 21
KO Up 24 2 7
Down 88 57 35
Table 2
A. Genes altered in expression after 1 wk exposure to crocidolite vs saline in WT mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
IQ motif-containing E Iqce AK006472 74239 5.26
RIKEN cDNA 2610110G12 gene 2610110G12Rik AK002569 73242 4.57
Nurim (nuclear envelope
membrane protein)
Nrm AK017439 106582 4.31
CDK5 regulatory subunit
associated protein 1
Cdk5rap1 NM_025876 66971 4.14
Keratin 85 Krt85 AY028606 114566 3.90
RIKEN cDNA 1200014M14 gene 1200014M14Rik NM_026173 67463 3.66
La ribonucleoprotein domain
family, member 6
Larp6 NM_026235 67557 3.55
Zinc ﬁnger protein 143 Zfp143 NM_009281 20841 3.54
Tripartite motif protein 21 Trim21 NM_009277 20821 3.53
ATP synthase, H+ transporting,
mitochondrial F0 complex,
subunit F
Atp5j NM_016755 11957 3.52
Phosphatidylinositol transfer
protein, beta
Pitpnb NM_019640 56305 3.40
Lactalbumin, alpha Lalba NM_010679 16770 3.33
5-hydroxytryptamine
(serotonin) receptor 5A
Htr5a NM_008314 15563 3.32
Epidermal growth factor receptor
pathway substrate 8
Eps8 NM_007945 13860 3.32
Regulator of G-protein signaling 5 Rgs5 NM_009063 19737 3.29
Mitogen activated protein kinase 8 Mapk8 NM_016700 26419 3.26
Eph receptor A4 Epha4 NM_007936 13838 3.23
Zinc ﬁnger protein 706 Zfp706 AB041652 68036 3.21
RIKEN cDNA 1700010I14 gene 1700010I14Rik NM_025851 66931 3.08
Wild-type p53-induced gene 1 Zmat3 NM_009517 22401 2.98
V-set and transmembrane domain
containing 2B
Vstm2b NM_021387 58188 2.95
5′-nucleotidase domain
containing 2
Nt5dc2 AK010966 70021 2.95
Neugrin, neurite outgrowth
associated
Ngrn NM_031375 83485 2.88
Phosphoenolpyruvate
carboxykinase 2 (mitochondrial)
Pck2 BC023437 74551 2.80
ELK4, member of ETS
oncogene family
Elk4 NM_007923 13714 2.78
Ribonuclease H2, subunit C Rnaseh2c NM_026616 68209 2.70
Transmembrane protein 101 Tmem101 BC011109 76547 2.67
TLC domain containing 1 Tlcd1 BC005702 68385 2.65
RIKEN cDNA 5730559C18 gene 5730559C18Rik NM_028872 67313 2.61
Ubiquitin carboxy-terminal
hydrolase L1
Uchl1 NM_011670 22223 2.52
RIKEN cDNA 2700049A03 gene 2700049A03Rik AK012399 76967 2.47
RIKEN cDNA 4930404N11 gene 4930404N11Rik AK015088 432479 2.43
Succinate-Coenzyme A ligase,
GDP-forming, beta subunit
Suclg2 AF058956 20917 2.39
BarH-like 1 (Drosophila) Barhl1 NM_019446 54422 2.38
Ectodermal-neural cortex 1 Enc1 NM_007930 13803 2.31
Interleukin 1 receptor
accessory protein
Il1rap NM_008364 16180 2.30
Calcium homeostasis endoplasmic
reticulum protein
Cherp AK017525 27697 2.28
CAMP-regulated
phosphoprotein 19
Arpp19 NM_021548 59046 2.24
Purinergic receptor P2X,
ligand-gated ion channel, 1
P2rx1 NM_008771 18436 2.24
Zinc ﬁnger protein of the
cerebellum 4
Zic4 NM_009576 22774 2.24
CD68 antigen Cd68 NM_009853 12514 2.24
Poly A binding protein,
cytoplasmic 1
Pabpc1 AK017655 66978 2.22
Tumor-associated calcium signal
transducer 2
Tacstd2 NM_020047 56753 2.18
Tripartite motif-containing 54 Trim54 NM_021447 58522 2.17
Protein arginine
N-methyltransferase 3
Prmt3 AK008118 71974 2.15
RIKEN cDNA 1600016N20 gene 1600016N20Rik AK005476 72000 2.15
Proprotein convertase s
ubtilisin/kexin type 1 inhibitor
Pcsk1n NM_013892 30052 2.15
Dynamin 2 Dnm2 NM_010561 16201 2.13
GA repeat binding protein,
beta 2
Gabpb2 AK020406 213054 2.12
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response to asbestos exposure by examining gene expression in
lungs derived from asbestos-exposed SPARC-null and wild-type
mice. The speciﬁc analyses in this report target those genes or
classes of genes in mouse lung tissue that change their expression
during exposure to asbestos, with or without the presence of
SPARC. This approach would logically describe a set of genes that
can only be activated by the combination of SPARC activity and
asbestos exposure.
Results and discussion
The central questions in this study center concern 1) the types
and magnitude of gene expression changes in SPARC-null mouse
lungs versus wild-type mouse lungs and 2) the types and
magnitude of changes seen in SPARC-null mouse lung following
the stress induced by asbestos exposure. SPARC-null and wild-type
mice were exposed to saline or crocidolite asbestos for periods of
one week, one month, or three months. Animals were euthanized
and lungs were removed and submitted for RNA expression
analysis. Microarray analysis was performed in a standard test
versus reference RNA co-hybridization on MWG 10K Group A
mouse oligo-based arrays. The use of reference RNA allowed the
comparison of values from multiple time points and exposure
conditions. Ten mice were pooled from each treatment group for
each data point. Pooling tends to obscure subtle gene expression
changes as the variance of ten biological specimens (mice)
generates a high baseline of transcriptional noise. Typically only
those expression changes that are of a large magnitude are seen in
pooled data. In order to focus primarily on genes that reproducibly
were altered, we performed two sequential threshold or ﬁlter
steps. Three replicate arrays were analyzed for each experiment
and mean and standard deviation was established for each gene.
Genes achieving a signiﬁcant (pb0.01) difference in expression
compared to the saline control experiments were further analyzed.
An arbitrary cutoff of two-fold up or down regulation (ratio of
b0.50 or N2) was used to further ﬁlter the data to delineate genes
that were highly activated or suppressed by asbestos exposure. A
general description of the numbers of genes meeting these criteria
is delineated in Table 1. The largest sets of gene expression
alterations occurred early (one week) in both wild-type and
SPARC-null mice, reﬂecting an acute response, but signiﬁcantly
more changes occurred in SPARC-null mice than the wild-type
mice at this time point (112 genes up or down in SPARC-null vs. 62
in wild-type mice). Smaller sets of gene expression changes take
place at the one month and three month time points (Table 1). The
resulting sets of gene transcripts for each time point and condition
are listed in Tables 2–4. The datasets are from one-week exposures
of crocidolite vs. saline in both wild-type and SPARC-null mice
(Table 2), one-month exposures of crocidolite vs. saline in both
wild-type and SPARC-null mice (Table 3), and three-month
exposures of crocidolite vs. saline in both wild-type and SPARC-
null mice (Table 4). Table 5 presents transcripts that were altered
in expression level in SPARC-null mice versus wild-type mice
without the addition of asbestos. This represents the steady state
gene expression differences within the lung and a potential list of
genes related to constitutive SPARC function. Genes with
Table 2 (continued)
A. Genes altered in expression after 1 wk exposure to crocidolite vs saline in WT mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
A kinase (PRKA) anchor
protein 8-like
Akap8l NM_017476 54194 2.08
Claudin 10, transcript variant 2 Cldn10 NM_021386 58187 2.07
RIKEN cDNA 2900083I11 gene 2900083I11Rik NM_021403 58212 2.07
RIKEN cDNA 1700106J16 gene 1700106J16Rik AK007129 74297 2.06
Ankyrin repeat and zinc
ﬁnger domain containing 1
Ankzf1 BC021773 74577 2.06
Small nuclear ribonucleoprotein
35 (U11/U12)
Snrnp35 AK018232 76167 2.04
RNA binding motif protein 3 Rbm3 NM_016809 19652 2.02
Mevalonate kinase Mvk NM_023556 17855 2.02
RIKEN cDNA 3110040N11 gene 3110040N11Rik NM_026077 67290 2.01
Proteoglycan 2, bone marrow Prg2 NM_008920 19074 2.00
Poly(rC) binding protein 2 Pcbp2 NM_011042 18521 0.50
SAP domain containing
ribonucleoprotein
Sarnp NM_025364 66118 0.49
Homeo box A11 Hoxa11 NM_010450 15396 0.30
B. Genes altered in expression after 1 wk exposure to crocidolite vs saline in
SPARC-null mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Ribonucleotide reductase M1 Rrm1 NM_009103 20133 2.79
Neurotrophin receptor
associated death domain
Nradd AK007483 67169 2.76
Odd Oz/ten-m homolog
3 (Drosophila)
Odz3 NM_011857 23965 2.75
Mediterranean fever Mefv NM_019453 54483 2.71
Ubiquitin speciﬁc
peptidase 25
Usp25 NM_013918 30940 2.59
Cleavage stimulation factor,
3′ pre-RNA, subunit 3
Cstf3 BC003241 228410 2.54
Golgi-associated PDZ
and coiled-coil
motif-containing
Gopc NM_053187 94221 2.51
DNA segment, Chr 10,
ERATO Doi 641, expressed
D10Ertd641e NM_025514 52717 2.35
Proteaseome (prosome,
macropain) 28 subunit, 3
Psme3 NM_011192 19192 2.29
Transforming growth
factor, beta 2
Tgfb2 NM_009367 21808 2.27
Parkinson disease
(autosomal recessive,
early onset) 7
Park7 NM_020569 57320 2.27
Bromodomain containing 7 Brd7 NM_012047 26992 2.24
Cholinergic receptor,
nicotinic, alpha
polypeptide 4
Chrna4 NM_015730 11438 2.22
Transforming growth factor
beta regulated gene 4
Tbrg4 U89434 21379 2.21
Artemin Artn NM_009711 11876 2.21
RIKEN cDNA
1700123I01 gene
1700123I01Rik AK007250 622554 2.18
Dachshund 1 (Drosophila) Dach1 AK018473 13134 2.16
EBNA1 binding protein 2 Ebna1bp2 AK007491 69072 2.13
Ngﬁ-A binding protein 2 Nab2 NM_008668 17937 2.12
Acyl-Coenzyme A binding
domain containing 5
Acbd5 AK005001 74159 2.08
Tetratricopeptide
repeat domain 33
Ttc33 AK013464 67515 2.07
SH2 domain protein 1B1 Sh2d1b1 NM_012009 26904 2.05
Neurogranin Nrgn NM_022029 64011 2.04
Syndecan 1 Sdc1 NM_011519 20969 2.03
Purinergic receptor P2X,
ligand-gated ion channel, 1
P2rx1 NM_008771 18436 0.50
Zinc ﬁnger, HIT domain
containing 2
Znhit2 NM_013859 29805 0.50
Tubulin polymerization-promoting
protein family member 3
Tppp3 NM_026481 67971 0.50
C-reactive protein,
pentraxin-related
Crp NM_007768 12944 0.50
ADP-ribosylation factor 4-like Arﬂ4 NM_025404 80981 0.50
Complexin 1 Cplx1 NM_007756 12889 0.50
Ribosomal protein S19 Rps19 NM_023133 20085 0.50
(continued on next page)
Table 2 (continued)
B. Genes altered in expression after 1 wk exposure to crocidolite vs saline in
SPARC-null mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
FK506 binding protein 2 Fkbp2 NM_008020 14227 0.50
V-set and immunoglobulin
domain containing 2
Vsig2 NM_020518 57276 0.49
Ubiquitin carboxy-terminal
hydrolase L1
Uchl1 NM_011670 22223 0.49
Vasorin Vasn AK012169 83945 0.49
CD36 antigen Cd36 NM_007643 12491 0.49
Pyridine nucleotide-disulphide
oxidoreductase domain 2
Pyroxd2 AK014668 74580 0.49
Proteoglycan 2,
bone marrow
Prg2 NM_008920 19074 0.49
Cell division cycle
associated 8
Cdca8 AK003755 52276 0.48
Open reading frame 19 ORF19 AJ304796 68767 0.48
A kinase (PRKA) anchor
protein 8-like
Akap8l NM_017476 54194 0.48
Rho guanine nucleotide
exchange factor (GEF) 3
Arhgef3 BC012262 71704 0.48
Carboxypeptidase X 1
(M14 family)
Cpxm1 NM_019696 319513 0.48
SAR1 gene homolog B
(S. cerevisiae)
Sar1b AK002327 66397 0.48
Hypoxia-inducible factor 1,
alpha subunit inhibitor
Hif1an AK009856 319594 0.48
Poly A binding protein,
cytoplasmic 1
Pabpc1 AK017655 66978 0.48
Intersectin 1 (SH3 domain
protein 1A)
Itsn1 NM_010587 16443 0.47
Abhydrolase domain
containing 2
Abhd2 NM_018811 54608 0.47
Serum amyloid A 3 Saa3 NM_011315 20210 0.47
Oxysterol binding
protein-like 7
Osbpl7 AK017095 71240 0.47
Tripartite
motif-containing 14
Trim14 AK017887 74735 0.47
Bcl-associated death promoter Bad NM_007522 12015 0.47
Stromal antigen 1 Stag1 AK017978 20842 0.46
CKLF-like MARVEL
transmembrane
domain containing 2B
Cmtm2b AK005970 75502 0.46
Nucleus accumbens
associated 2,
BEN and BTB (POZ)
domain containing
Nacc2 NM_026495 67991 0.46
Exosome component 6 Exosc6 AK012102 72544 0.45
Engrailed 2 En2 NM_010134 13799 0.45
B-cell CLL/lymphoma 7A Bcl7a AK014498 77045 0.45
Nuclear protein 1 Nupr1 NM_019738 56312 0.45
Mortality factor 4 like 1 Morf4l1 AF319621 21761 0.45
Synaptic vesicle
glycoprotein 2c
Sv2c AK015921 75209 0.45
Tripartite
motif-containing 54
Trim54 NM_021447 58522 0.45
General transcription
factor II A, 1
Gtf2a1 NM_031391 83602 0.45
RIKEN cDNA
4933421I07 gene
4933421I07Rik NM_027702 71162 0.44
Phosphodiesterase 9A Pde9a NM_008804 18585 0.44
Phosphatidylinositol
3-kinase, regulatory
subunit, polypeptide 2
(p85 beta)
Pik3r2 NM_008841 18709 0.44
Williams–Beuren syndrome
chromosome region 16
homolog (human)
Wbscr16 NM_033572 94254 0.44
RIKEN cDNA
8030423J24 gene
8030423J24Rik AK020194 77166 0.44
Tctex1 domain containing 2 Tctex1d2 AK002589 66061 0.43
YdjC homolog (bacterial) Ydjc AK007503 69101 0.43
Collagen triple helix repeat
containing 1
Cthrc1 AK003674 68588 0.43
Inhibitor of DNA binding 1 Id1 AK008264 15901 0.43
(continued on next page)
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Table 2 (continued)
B. Genes altered in expression after 1 wk exposure to crocidolite vs saline in
SPARC-null mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Ribosomal RNA processing 1
homolog (S. cerevisiae)
Rrp1 NM_010925 18114 0.43
Anaphase-promoting
complex subunit 5
Anapc5 AK012579 59008 0.43
Sphingomyelin
phosphodiesterase 3,
neutral
Smpd3 NM_021491 58994 0.43
Tetratricopeptide repeat
domain 19
Ttc19 AK008442 72795 0.42
CD68 antigen Cd68 NM_009853 12514 0.42
Gasdermin C2 Gsdmc2 AK006248 74236 0.42
Transmembrane protein 206 Tmem206 NM_025864 66950 0.42
Calcium homeostasis
endoplasmic reticulum
protein
Cherp AK017525 27967 0.42
Thyroid hormone receptor
interactor 10
Trip10 NM_134125 106628 0.42
RAB10, member RAS
oncogene family
Rab10 NM_016676 19325 0.42
Leukotriene B4 receptor 2 Ltb4r2 NM_020490 57260 0.42
RIKEN cDNA
1700106J16 gene
1700106J16Rik AK007129 74297 0.41
Secreted frizzled-related
sequence protein 1
Sfrp1 NM_013834 20377 0.41
Pterin 4 alpha carbinolamine
dehydratase/dimerization
cofactor of hepatocyte nuclear
factor 1 alpha (TCF1) 2
Pcbd2 AK012465 72562 0.41
Protein tyrosine
phosphatase,
receptor-type, F interacting
protein, binding protein 2
Ppﬁbp2 NM_008905 19024 0.41
Selenoprotein W, muscle 1 Sepw1 NM_009156 20364 0.41
Testis derived transcript Tes NM_011570 21753 0.40
Vav 3 oncogene Vav3 NM_020505 57257 0.40
Reactive oxygen
species modulator 1
Romo1 NM_025946 67067 0.40
Jerky Jrk NM_008415 16469 0.39
RIKEN cDNA
0610038L08 gene
0610038L08Rik AK002805 0.39
Solute carrier organic anion
transporter family,
member 3a1
Slco3a1 NM_023908 108116 0.39
Autophagy-related 3 (yeast) Atg3 NM_026402 67841 0.38
Sortilin 1 Sort1 NM_019972 20661 0.38
NADH dehydrogenase
(ubiquinone) 1 alpha
subcomplex 10
Ndufa10 NM_024197 67273 0.36
Tumor-associated calcium
signal transducer 2
Tacstd2 NM_020047 56753 0.36
RIKEN cDNA
A030009H04 gene
A030009H04Rik NM_020591 80515 0.36
Guanylate cyclase 2e Gucy2e NM_008192 14919 0.35
Lysozyme-like 1 Lyzl1 NM_026092 67328 0.35
Nuclear factor of activated
T-cells 5
Nfat5 NM_018823 54446 0.33
RIKEN cDNA
E130309D02 gene
E130309D02Rik NM_017467 54201 0.33
RIKEN cDNA
2310035C23 gene
2310035C23Rik AK009628 227446 0.33
Claudin 10A Cldn10a NM_021386 58187 0.32
Defects in morphology
1 homolog (S. cerevisiae)
Dem1 AK014134 73172 0.31
Kelch repeat and BTB (POZ)
domain containing 11
Kbtbd11 AK015509 74901 0.31
Spectrin beta 4 Spnb4 AF203696 80297 0.31
RIKEN cDNA
4933417A18 gene
4933417A18Rik NM_025750 66761 0.29
Neuroligin 1 Nlgn1 BC005523 192167 0.18
Testis-speciﬁc serine
kinase 4
Tssk4 AK016890 71099 0.11
Table 2 (continued) Table 3
A. Genes altered in expression after 1 mo exposure to crocidolite vs saline in WT mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Claudin 10A Cldn10a NM_021386 58187 3.78
COMM domain containing 9 Commd9 AK007640 76501 3.44
BTB (POZ) domain containing 17 Btbd17 AK005160 72014 3.36
Sema domain, immunoglobulin
domain (Ig), short basic domain,
secreted, (semaphorin) 3 F
Sema3f NM_011349 20350 3.31
SRY-box containing gene 3 Sox3 NM_009237 20675 3.25
Tumor-associated calcium signal
transducer 2
Tacstd2 NM_020047 56753 3.12
Proteoglycan 2, bone marrow Prg2 NM_008920 19074 2.95
Fanconi anemia,
complementation group G
Fancg NM_053081 60534 2.84
ADP-ribosylation factor 3 Arf3 AK017249 11842 2.83
RIKEN cDNA 3110040N11 gene 3110040N11Rik NM_026077 67290 2.82
Spectrin beta 4 Spnb4 AF203696 80297 2.54
Melan-A Mlana AK020928 77836 2.53
RIKEN cDNA 1700106J16 gene 1700106J16Rik AK007129 74297 2.45
Ring ﬁnger protein 167 Rnf167 BC010777 70510 2.44
Nuclear factor of activated T-cells 5 Nfat5 NM_018823 54446 2.39
RIKEN cDNA 0610010K14 gene 0610010K14Rik AK002491 104457 2.39
Tripartite motif-containing 54 Trim54 NM_021447 58522 2.32
Exportin 5 Xpo5 AK012248 72322 2.28
Oligodendrocyte transcription
factor 1
Olig1 NM_016968 50914 2.25
Yippee-like 3 (Drosophila) Ypel3 AK004431 66090 2.24
Pyruvate carboxylase Pcx NM_008797 18563 2.22
MRV integration site 1 Mrvi1 NM_010826 17540 2.20
Resistin like alpha Retnla NM_020509 57262 2.19
Proteasome (prosome, macropain)
assembly chaperone 3)
Psmg3 AK019558 66506 2.17
Inhibitor of DNA binding 1 Id1 AK008264 15901 2.11
NK1 transcription factor related,
locus 2 (Drosophila)
Nkx1-2 NM_009123 20231 2.10
Autophagy-related 3 (yeast) Atg3 NM_026402 67841 2.09
Exosome component 6 Exosc6 AK012102 72544 2.04
Unc-51-like kinase 4 (C. elegans) Ulk4 AK016524 209012 2.01
ArsA (bacterial) arsenite
transporter, ATP-binding,
homolog 1
Asna1 NM_019652 56495 2.00
Interferon induced
transmembrane protein 7
Iﬁtm7 AK017110 74482 2.00
Myeloid ecotropic viral
integration site 1
Meis1 NM_010789 17268 0.48
Poly(rC) binding protein 2 Pcbp2 NM_011042 18521 0.44
DNA methyltransferase
1-associated protein 1
Dmap1 NM_023178 66233 0.40
B. Genes altered in expression after 1 mo exposure to crocidolite vs saline in
SPARC-null mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Niemann Pick type C2 Npc2 NM_023409 67963 2.23
Trichorhinophalangeal
syndrome I (human)
Trps1 NM_032000 83925 2.00
NADH dehydrogenase
(ubiquinone) 1 alpha
subcomplex, 7 (B14.5a)
Ndufa7 NM_023202 66416 0.50
MAP/microtubule
afﬁnity-regulating kinase 2
Mark2 NM_007928 13728 0.50
RIKEN cDNA
4933427E13 gene
4933427E13Rik AK016948 71234 0.50
Coatomer protein complex
subunit alpha
Copa BC005609 12847 0.50
Janus kinase 3 Jak3 NM_013564 16336 0.50
Pterin 4 alpha carbinolamine
dehydratase/dimerization
cofactor of hepatocyte
nuclear factor 1 alpha (TCF1) 2
Pcbd2 AK012465 72562 0.49
RIKEN cDNA
4930430A15 gene
4930430A15Rik NM_026248 67575 0.49
Creatine kinase,
mitochondrial 1, ubiquitous
Ckmt1 NM_009897 12716 0.49
Wingless-related MMTV
integration site 6
Wnt6 NM_009526 22420 0.49
104 M.A. Pershouse et al. / Genomics 94 (2009) 101–109
Table 3 (continued)
B. Genes altered in expression after 1 mo exposure to crocidolite vs saline in
SPARC-null mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Proﬁlin 1 Pfn1 NM_011072 18643 0.49
Polymerase (RNA) II
(DNA directed) polypeptide J
Polr2j NM_011293 20022 0.48
Wingless-related MMTV
integration site 3
Wnt3 NM_009521 22415 0.48
RecQ protein-like Recql NM_023042 19691 0.48
RNA binding motif protein 8a Rbm8a NM_025875 60365 0.48
Secreted frizzled-related
sequence protein 1
Sfrp1 NM_013834 20377 0.48
Sloan-Kettering viral
oncogene homolog
Ski AK019148 20481 0.48
Developmental pluripotency
associated 5A
Dppa5a NM_025274 434423 0.48
Solute carrier family 39
(metal ion transporter),
member 5
Slc39a5 AK007473 72002 0.48
RIKEN cDNA
4933430H15 gene
4933430H15Rik AK016993 74485 0.48
Glycosyltransferase 8 domain
containing 2
Glt8d2 AK003894 74782 0.48
RIKEN cDNA
3110040N11 gene
3110040N11Rik NM_026077 67290 0.47
DNA methyltransferase
1-associated protein 1
Dmap1 NM_023178 66233 0.47
RIKEN cDNA
9430038I01 gene
9430038I01Rik AK020460 77252 0.47
DEAH (Asp-Glu-Ala-His) box
polypeptide 30
Dhx30 NM_133347 72831 0.47
Neuroblastoma, suppression
of tumorigenicity 1
Nbl1 NM_008675 17965 0.47
Tnf receptor associated
factor 4
Traf4 NM_009423 22032 0.46
Spastic paraplegia
21 homolog (human)
Spg21 NM_138584 27965 0.46
FK506 binding protein 2 Fkbp2 NM_008020 14227 0.46
RIKEN cDNA
C330007P06 gene
C330007P06Rik AK021190 77644 0.46
Growth factor receptor
bound protein 14
Grb14 NM_016719 50915 0.46
Frequently rearranged in
advanced T-cell lymphomas
Frat1 NM_008043 14296 0.46
CKLF-like MARVEL
transmembrane domain
containing 7
Cmtm7 NM_133978 102545 0.45
Solute carrier family 4
(anion exchanger),
member 3
Slc4a3 AK020943 20536 0.45
YdjC homolog (bacterial) Ydjc AK007503 69101 0.45
URB1 ribosome biogenesis 1
homolog (s. cerevisiae)
Urb1 AK017495 207932 0.44
Cholinergic receptor,
muscarinic 3, cardiac
Chrm3 NM_033269 12671 0.44
RIKEN cDNA
8030423J24 gene
8030423J24Rik AK020194 77166 0.43
Repetin Rptn NM_009100 20129 0.42
Sortilin 1 Sort1 NM_019972 20661 0.42
Asporin Aspn AF316825 66695 0.41
Solute carrier family 1
(glial high afﬁnity
glutamate transporter),
member 3
Slc1a3 AF330257 20512 0.41
Zinc ﬁnger protein 46 Zfp46 NM_009557 22704 0.41
Protein-L-isoaspartate
(d-aspartate)
O-methyltransferase 1
Pcmt1 NM_008786 18537 0.41
Replication factor C
(activator 1) 3
Rfc3 BC026795 69263 0.40
Cyclin H Ccnh NM_023243 66671 0.40
Prolyl endopeptidase Prep NM_011156 19072 0.40
Fanconi anemia,
complementation group G
Fancg NM_053081 60534 0.39
Keratin 35 Krt35 NM_016880 53617 0.39
Hyperpolarization-activated,
cyclic nucleotide-gated K+ 2
Hcn2 NM_008226 15166 0.39
(continued on next page)
Table 3 (continued)
B. Genes altered in expression after 1 mo exposure to crocidolite vs saline in
SPARC-null mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Zinc ﬁnger and BTB domain
containing 4
Zbtb4 AK009517 75580 0.38
Coenzyme Q10 homolog
B (S. cerevisiae)
Coq10b AK002294 67876 0.37
Nuclear receptor subfamily 6,
group A, member 1
Nr6a1 NM_010264 14536 0.35
Calreticulin 3 Calr3 AK006582 73316 0.33
Neurensin 1 Nrsn1 NM_009513 22360 0.31
Ubiquitin carboxy-terminal
hydrolase L1
Uchl1 NM_011670 22223 0.31
Hyaluronoglucosaminidase 2 Hyal2 NM_019742 80385 0.30
N-6 adenine-speciﬁc
DNA methyltransferase 2
N6amt2 NM_026526 68043 0.27
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signiﬁcance of pb0.01 are listed. Notable genes in the list related
to ﬁbrosis, bone formation, lung function, or SPARC mechanisms
are Gdf5, Sftpc, Fgf13, Saa3, Zmat3, and Wnt3.
Several transcripts were alternatively measured by real-time PCR
for validation of the array. The values for both analyses are presented
in Table 6.
GoMiner analysis combined with a cutoff of greater than 2-fold
expression changes was used to derive a set of functional (gene
ontology) groups that were altered. These groups were examined at
each of the timepoints. These groups are described in the text below
and full tables of the results have been uploaded to the NCBI-GEO
database (www.ncbi.nlm.nih.gov/geo/).
A comparison of transcriptional changes in mouse lung following
various times of exposure to asbestos was studied in this report. The
experimental design involved pooling lung RNA from a group of 10
mice for each condition/time point. This tended to compromise the
smaller gene expression changes due to the variability inherent in
mouse lung gene expression frommouse to mouse. However, this had
the advantage of providing a biological ﬁlter for the data, only
allowing signiﬁcant and profound changes to survive the analysis. In
addition, a fold-change cutoff of two-fold was applied to further ﬁlter
the data. Asbestos exposures of one week, one month, and three
months provided for examination of the process of the mouse lung
response to asbestos at critical time intervals. Early response may
reﬂect signiﬁcant gene expression activity involved in recognition,
immune response, and signal transduction or in the case of the
knockout mice, a larger number of pathways dysregulated by the
absence of SPARC. The largest number of transcription changes
occurred at this time point as shown in Table 2. Later time points
may reﬂect the physical processes of ﬁbrosis and resolution. In
separate reports ([16], M. Smart et al., manuscript submitted), the
level of ﬁbrosis as assessed by hydroxyproline levels was studied in
these mice. Fibrosis was signiﬁcant by one month in both wild-type
and SPARC-null animals, however, at three months after asbestos
instillation ﬁbrosis continued to increase in wild-type mice but had
been reduced to control levels in SPARC-null mice, demonstrating a
resolution of ﬁbrosis in the absence of SPARC expression. This ﬁnding
is similar to that of Strandjord et al. [17] who found that Sparc-null
mice had reduced collagen accumulation compared to wild-type mice
after bleomycin exposure. Distinct gene sets were altered at this later
time point and, interestingly, more genes were down-regulated than
up-regulated by three months after exposure. This may reﬂect an
attempt by the lung to modulate or dampen the response to stress. It
may well bemore successful in SPARC-null thanwild-typemice due to
the absence of positive regulators of ﬁbrosis. SPARC normally plays a
key role in TGF-β signaling to c-jun/AP-1/junk kinase and a
Table 4
A. Genes altered in expression after 3 mo exposure to crocidolite vs saline in WT mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Guanine nucleotide binding
protein, beta 1
Gnb1 NM_008142 14688 3.94
Tripartite motif-containing 59 Trim59 NM_025863 66949 3.34
Intersectin 1 (SH3 domain
protein 1A)
Itsn1 NM_010587 16443 3.15
ADP-ribosylation factor-like 10 Arl10 NM_019968 56795 3.08
Protein-L-isoaspartate
(d-aspartate)
O-methyltransferase 1
Pcmt1 NM_008786 18537 3.02
ATP-binding cassette, subfamily A
(ABC1), member 14
Abca14 AK007156 67928 2.89
Ubiquitin-conjugating
enzyme E2S
Ube2s NM_133777 77891 2.83
Catechol-O-methyltransferase
domain containing 1
Comtd1 AK007659 69156 2.67
Kelch repeat and BTB (POZ)
domain containing 11
Kbtbd11 AK015509 74901 2.66
Solute carrier family 1
(glial high afﬁnity glutamate
transporter), member 3
Slc1a3 AF330257 20512 2.61
Calreticulin 3 Calr3 AK006582 73316 2.58
Cyclin M2 Cnnm2 NM_033569 94219 2.52
Alveolar soft part sarcoma
chromosome region, candidate
1 (human)
Aspscr1 BC019177 68938 2.45
Protein kinase, cGMP-dependent,
type I
Prkg1 AK020237 19091 2.43
Lactalbumin, alpha Lalba NM_010679 16770 2.39
Rho GTPase activating protein 10 Arhgap10 AK002788 78514 2.36
Soc-2 (suppressor of clear)
homolog (C. elegans)
Shoc2 NM_019658 56392 2.31
Myosin, heavy polypeptide 3,
skeletal muscle, embryonic
Myh3 M74753 17883 2.29
Hexokinase 1 Hk1 NM_010438 15275 2.27
Phenylalanine hydroxylase Pah NM_008777 18478 2.27
GA repeat binding protein, beta 2 Gabpb2 AK020406 213054 2.27
IQ motif-containing E Iqce AK006472 74239 2.27
Gamma-aminobutyric acid
(GABA-A) receptor,
subunit alpha 3
Gabra3 NM_008067 14396 2.26
Alanyl (membrane)
aminopeptidase
Anpep NM_008486 16790 2.24
URB1 ribosome biogenesis 1
homolog (S. cerevisiae)
Urb1 AK017495 207932 2.24
Dysferlin Dysf AF188290 26903 2.23
DEAD (Asp-Glu-Ala-Asp) box
polypeptide 3, Y-linked
Ddx3y AJ007376 26900 2.22
Component of oligomeric golgi
complex 1
Cog1 NM_013581 16834 2.21
Zinc ﬁnger, HIT domain
containing 2
Znhit2 NM_013859 29805 2.21
Nuclear receptor subfamily 6,
group A, member 1
Nr6a1 NM_010264 14536 2.17
BTB and CNC homology 1 Bach1 NM_007520 12013 2.17
Ts translation elongation
factor, mitochondrial
Tsfm AK012240 66399 2.16
Epiregulin Ereg NM_007950 13874 2.16
Heterogeneous nuclear
ribonucleoprotein A1
Hnrnpa1 NM_010447 15382 2.14
Abhydrolase domain containing 2 Abhd2 NM_018811 54608 2.12
LSM5 homolog, U6 small nuclear
RNA associated (S. cerevisiae)
Lsm5 NM_025520 66373 2.11
Ubiquitin carboxy-terminal
hydrolase L1
Uchl1 NM_011670 22223 2.11
Distal-less homeobox 3 Dlx3 NM_010055 13393 2.10
Vacuolar protein sorting 11 (yeast) Vps11 BC016258 71732 2.10
Human immunodeﬁciency virus
type I enhancer binding protein 3
Hivep3 NM_010657 16656 2.05
RAB15 effector protein Rep15 NM_025620 66532 2.03
Synaptotagmin V Syt5 NM_016908 53420 2.03
Transmembrane protein 51 Tmem51 BC003277 214359 2.01
Calcium/calmodulin-dependent
protein kinase II inhibitor 2
Camk2n2 AK013788 73047 2.01
Table 4 (continued)
A. Genes altered in expression after 3 mo exposure to crocidolite vs saline in WT mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Ribonucleotide reductase M1 Rrm1 NM_009103 20133 0.50
Sema domain, immunoglobulin
domain (Ig), short basic domain,
secreted, (semaphorin) 3 F
Sema3f NM_011349 20350 0.50
Transcription factor AP-2,
gamma
Tcfap2c NM_009335 21420 0.49
Transketolase Tkt NM_009388 21881 0.49
Zinc ﬁnger protein 97 Zfp97 NM_011765 22759 0.48
ADP-ribosylation factor 3 Arf3 AK017249 11842 0.47
Glyceronephosphate
O-acyltransferase
Gnpat NM_025615 66523 0.45
RIKEN cDNA 4930529I22 gene 4930529I22Rik AK015936 75231 0.43
RIKEN cDNA 1700011H22 gene 1700011H22Rik AK005867 69314 0.40
Ribosomal protein L3 Rpl3 NM_013762 27367 0.39
Adrenergic receptor, alpha 2a Adra2a NM_007417 11551 0.38
ATP synthase, H+ transporting,
mitochondrial F0 complex,
subunit F
Atp5j NM_016755 11957 0.37
CD247 antigen Cd247 NM_031162 12503 0.37
RIKEN cDNA 5730455O13 gene 5730455O13Rik AK017666 70567 0.35
Cut-like 2 (Drosophila) Cutl2 NM_007804 13048 0.33
NOP17 Nop17 AK004341 68845 0.31
RIKEN cDNA 1810063B07 gene 1810063B07Rik AK015650 67509 0.30
Basic helix-loop-helix
family, member e22
Bhlhe22 NM_021560 59058 0.27
Succinate-Coenzyme A ligase,
GDP-forming, beta subunit
Suclg2 AF058956 20917 0.26
V-set and transmembrane
domain containing 2B
Vstm2b NM_021387 58188 0.23
ELK4, member of ETS
oncogene family
Elk4 NM_007923 13714 0.22
B. Genes altered in expression after 3 mo exposure to crocidolite vs saline in
SPARC-null mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
RIKEN cDNA
4933417A18 gene
4933417A18Rik NM_025750 66761 2.89
Ring ﬁnger protein 167 Rnf167 BC010777 70510 2.61
Actinin, alpha 1 Actn1 NM_011501 109711 2.36
Longevity assurance homolog
5 (S. cerevisiae)
Lass5 AY029533 71949 2.36
ST3 beta-galactoside
alpha-2,3-sialyltransferase 5
St3gal5 NM_011375 20454 2.30
Exportin 5 Xpo5 AK012248 72322 2.14
TLC domain containing 1 Tlcd1 BC005702 68385 2.03
Purinergic receptor P2X,
ligand-gated ion channel, 1
P2rx1 NM_008771 18436 0.50
G-protein-coupled receptor
kinase-interactor 2
Git2 NM_019834 26431 0.50
Serum amyloid A 3 Saa3 NM_011315 20210 0.50
Kelch-like 35 (Drosophila) Klhl35 AK013012 72184 0.50
Proﬁlin 1 Pfn1 NM_011072 18643 0.50
DnaJ (Hsp40) homolog,
subfamily A, member 1
Dnaja1 NM_011875 23997 0.50
GA repeat binding protein,
beta 2
Gabpb2 AK020406 213054 0.49
RIKEN cDNA 2210417D09 gene 2210417D09Rik NM_025620 66532 0.49
Attractin Atrn NM_009730 11990 0.49
Protein arginine
N-methyltransferase 5
Prmt5 AF167573 27374 0.49
Synaptotagmin V Syt5 NM_016908 53420 0.49
MAP kinase-activated protein
kinase 5
Mapkapk5 NM_010765 17165 0.49
RAB33B, member of RAS
oncogene family
Rab33b NM_016858 19338 0.49
Calcium homeostasis
endoplasmic reticulum
protein
Cherp AK017525 27967 0.48
RIKEN cDNA
4933400F03 gene
4933400F03Rik AK016591 71013 0.48
Solute carrier organic anion
transporter family, member 6c1
Slco6c1 AK016647 74441 0.47
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Table 4 (continued)
B. Genes altered in expression after 3 mo exposure to crocidolite vs saline in
SPARC-null mice
Name Symbol ID Entrez
GeneID
Cro/sal
ratio
Hyaluronoglucosaminidase 2 Hyal2 NM_019742 80385 0.47
Complexin 1 Cplx1 NM_007756 12889 0.46
RIKEN cDNA
2700046A07 gene
2700046A07Rik AK020725 78449 0.46
Phosphopantothenoylcysteine
decarboxylase
Ppcdc BC004779 66812 0.45
Inhibitor of DNA binding 1 Id1 AK008264 15901 0.45
Retinol binding protein 1,
cellular
Rbp1 NM_011254 19659 0.44
Guanylate cyclase 2e Gucy2e NM_008192 14919 0.43
Calreticulin 3 Calr3 AK006582 73316 0.43
RIKEN cDNA 9430038I01 gene 9430038I01Rik AK020460 77252 0.43
Reactive oxygen species
modulator 1
Romo1 NM_025946 67067 0.43
Soc-2 (suppressor of clear)
homolog (C. elegans)
Shoc2 NM_019658 56392 0.42
Bromodomain containing 4 Brd4 NM_020508 57261 0.41
Pancreatic and duodenal
homeobox 1
Pdx1 NM_008814 18609 0.41
RIKEN cDNA
4933430H15 gene
4933430H15Rik AK016993 74485 0.41
Arylformamidase Afmid AK018563 71562 0.39
YdjcC homolog (bacterial) Ydjc AK007503 69101 0.38
N-6 adenine-speciﬁc DNA
methyltransferase 2
N6amt2 NM_026526 68043 0.37
Surfeit gene 6 Surf6 NM_009298 20935 0.37
RIKEN cDNA 8030423J24 gene 8030423J24Rik AK020194 77166 0.33
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transforming growth factor beta 2 (Tgfb2) gene and the transforming
growth factor beta regulated gene 4 (Tbrg4) are both up-regulated at
one week in SPARC-null mice.
In terms of classes of genes determined by GoMiner analysis
(NCBI-GEO database) that would have been expected to be altered
based on the known function of SPARC versus the observed data, there
was a reasonable correlation. The largest number of genes, and thus
the largest number of gene categories, was altered at the one-week
time point. In the mouse lung, many processes can be expected to be
taking place, such as immune recognition, inﬂammation, attempts at
asbestos removal, vascularization, and cell–cell communication. We
saw signiﬁcant expression changes in genes involved in circulation,
growth factor activity, response to bacterium and response to other
organisms (possibly similar to genes involved in asbestos response),
energy use, and microtubule mobilization.
At one month post asbestos instillation, we might expect that
SPARC-null micewould have a decrease in activity in pathways related
to ﬁbrosis, although the SPARC-null mice had similar levels of ﬁbrosis
at one month in studies employing hydroxyproline as a measure of
ﬁbrosis [A. Smartt et al., manuscript submitted]. We saw signiﬁcant
changes in GoMiner categories titled cell soma, regulation of actin
ﬁlament polymerization, Golgi-associated vesicles, and the Wnt
receptor signaling pathway. The Wnt receptor signaling pathway has
been implicated in many related processes, including mesothelioma
formation, tissue regeneration, and ﬁbrosis [18–20].
After three months exposure to instilled asbestos, there were clear
differences in the levels of ﬁbrosis in SPARC-null versus wild-type
mice. We might expect several categories of genes to be altered as the
ﬁbrosis resolved in SPARC-null mice by 3 months. Interestingly, we
found signiﬁcant numbers of genes altered in the GoMiner categories
of lyase activity, energy production, membrane activity, and transport.
An intriguing result is that each time point reﬂects changes in
gene expression for a unique set of genes. Very few genes are
altered at all three time points, or even at two time points. Thisresult suggests that each timepoint is distinct in terms of cellular
processes taking place. At all time points, in SPARC-null mice more
genes are down-regulated than up-regulated. This may be due to
the absence of TGF-β signaling, as well as the absence of a robust
ﬁbrotic process.
Finally, we examined the set of genes that were distinctly
expressed when SPARC-null mice were compared to wild-type mice
without the exposure to asbestos. Several genes in Table 5 had
known roles in SPARC or ﬁbrosis-related processes. These included
Gdf5, Sftpc, Fgf13, Saa3, Zmat3, and Wnt3. Gdf5 encodes growth
differentiation factor 5, a cartilage morphogenic factor and regulator
of apoptosis [21]. Sftpa1 encodes surfactant associated protein-C, an
important innate host defense protein [22]. Fgf13 is a ﬁbroblast
growth factor [23], while Saa3 is a key protein involved in the early
inﬂammatory response [24]. Zmat3 is involved in p53-mediated
regulation of apoptosis [25], and Wnt3 is a key molecule in the
ﬁbrotic process [26].
In summary, differential gene expression analysiswas performed at
various times following asbestos exposure in SPARC-null or wild-type
mice to assess the role of SPARC in the ﬁbrotic process. Tens of genes
(61) were identiﬁed that vary in their expression at least 2 fold at a
signiﬁcance level of b0.01 between SPARC-null and wild-type mice
without asbestos exposure, and additional transcripts were identiﬁed
that may play a role in SPARC modulation of the ﬁbrotic response to
asbestos or other stressors in the lung. This report is a companion to
another report ([16], A. Smartt et al., manuscript submitted) in which
ﬁbrosis was directly quantiﬁed over this time frame. Thus the
biological endpoint of ﬁbrosis and its severity can be correlated with
the changes in gene transcription. Following validation of key
transcripts by alternative methodology, an informative model of
SPARC-mediated modulation of ﬁbrosis can be described. In order to
explain the remodeling or reduction in ﬁbrosis present in SPARC-null
mice, it is important to have a broad picture of the molecular changes
that are or are not taking place in this tissue. The ﬁnding of ﬁbrosis
resolution is rare in the literature, and considering the absence of
effective therapies for ﬁbrosis in humans exposed to asbestos these
ﬁndings can be very useful in understanding the molecular mechan-
isms taking place in these mice, and potentially can be exploited for
therapeutic advantage or increased diagnostic advantage.
Materials and methods
Asbestos
Crocidolite asbestos was obtained from the Research Triangle
Institute (Research Triangle Park, NC). Samples were freshly prepared
in sterile phosphate-buffered saline (PBS, pH 7.4) and sonicated before
instillation.
Mouse treatment
All animal protocols were approved by the University of Montana
Institutional Animal Care and Use Committee. Mice were exposed to
asbestos according to methods previously described [27]. Brieﬂy,
pathogen-free 6–8 week old female and male C57Bl/6 WT mice and
SPARC-null mice on a C57BL/6 background (Sparctm1Hwe) [17] were
instilled intratracheally with 100 µg of crocidolite asbestos in 30 µl
sterile PBS under anesthesia (n=8–10 for each condition/time point).
Control mice received only sterile PBS. Mice were euthanized 1 week,
1 month, or 3 months after instillation. The left lungs of the mice were
removed for RNA isolation.
RNA isolation
Lung tissue samples were homogenized in 1 ml of TRIZOL and
RNA isolated following the manufacturer's protocol (Invitrogen,
Table 5
Transcripts up- or down-regulated in SPARC-null mouse lung relative to wild-type mouse lung with no asbestos exposure.
Name Symbol ID Entrez GeneID Null v wt fold change p
Growth differentiation factor 5 Gdf5 NM_008109 14563 −6.603053459 0.001926001
Thymosin, beta 4, X chromosome Tmsb4x NM_021278 19241 −5.111212043 1.10284E−05
Surfactant associated protein C Sftpc NM_011359 20389 −4.682311004 0.001250906
RIKEN cDNA 2610110G12 gene 2610110G12Rik AK002569 73242 13.47656779 7.5926E−05
Tripartite motif protein 21 Trim21 NM_009277 20821 13.47563166 0.000378362
Myeloid leukemia factor 2 Mlf2 BC003975 30853 12.93589603 0.003748798
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F Atp5j NM_016755 11957 11.46301407 0.008790679
Basic helix-loop-helix family, member e22 Bhlhe22 NM_021560 59058 11.09411758 1.61834E−05
RIKEN cDNA 1200014M14 gene 1200014M14Rik NM_026173 67463 10.50602164 2.19525E−05
Meiotic recombination 11 homolog A (S. cerevisiae) Mre11a NM_018736 17535 8.276931256 0.000635392
Zinc ﬁnger protein 143 Zfp143 NM_009281 20841 7.708840996 0.008307884
Translocase of inner mitochondrial membrane 13 homolog (yeast) Timm13 NM_013895 30055 6.832737855 0.003679235
Fibroblast growth factor 13 Fgf13 NM_010200 14168 6.725304713 0.000701377
Regulator of G-protein signaling 5 Rgs5 NM_009063 19737 6.591743848 0.003335591
RIKEN cDNA 2700049A03 gene 2700049A03Rik AK012399 76967 6.537417400 0.000309559
Phosphatidylinositol transfer protein, beta Pitpnb NM_019640 56305 6.473618685 0.000462272
RIKEN cDNA 1110034A24 gene 1110034A24Rik AK012767 109065 5.539183244 0.000340335
RIKEN cDNA 4933417A18 gene 4933417A18Rik NM_025750 66761 5.387423813 0.000444828
SAPS domain family, member 2 Saps2 AK004079 71474 5.326741418 5.29287E−05
Progestin and adipoQ receptor family member VII Paqr7 AK009450 71904 5.281466348 0.00121557
Neugrin, neurite outgrowth associated Ngrn NM_031375 83485 5.135453101 0.004127214
Wild-type p53-induced gene 1 Zmat3 NM_009517 22401 4.860390511 0.000921368
Receptor-interacting serine-threonine kinase 4 Ripk4 NM_023663 72388 4.804286301 0.000656553
Transmembrane protein 101 Tmem101 BC011109 76547 4.239472296 0.001131018
Tuftelin interacting protein 11 Tﬁp11 NM_018783 54723 4.223368600 0.000455202
Potassium intermediate/small conductance
calcium-activated channel, subfamily N, member 1
Kcnn1 NM_032397 84036 3.997615531 0.000806639
Wingless-related MMTV integration site 3 Wnt3 AK015090 22415 3.155860305 0.010678552
Heterogeneous nuclear ribonucleoprotein A2/B1 Hnrnpa2b1 NM_016806 53379 3.874349633 0.008887483
Mortality factor 4 like 1 Morf4l1 AF319621 21761 3.846591079 0.000870826
Hyperpolarization-activated, cyclic nucleotide-gated K+ 2 Hcn2 NM_008226 15166 3.796178226 0.003535704
V-myc myelocytomatosis viral oncogene homolog 1,
lung carcinoma derived (avian)
Mycl1 NM_008506 16918 3.733283540 0.001757698
GA repeat binding protein, beta 2 Gabpb2 AK020406 213054 3.698137887 0.001227329
Intersectin 1 (SH3 domain protein 1A) Itsn1 NM_010587 16443 3.666080672 2.03801E−05
ELAV (embryonic lethal, abnormal vision,
Drosophila)-like 3 (Hu antigen C)
Elavl3 U29148 15571 3.654357562 4.57513E−05
Galanin Gal NM_010253 14419 3.647545508 0.000218062
Serum amyloid A 3 Saa3 NM_011315 20210 3.547617186 0.000401068
Prokineticin 2 Prok2 NM_015768 50501 3.520065635 0.001032535
Rhodopsin Rho BC013125 212541 3.493786385 0.00304529
SAR1 gene homolog B (S. cerevisiae) Sar1b AK002327 66397 3.490867287 7.85482E−05
Cyclin-dependent kinase inhibitor 3 Cdkn3 AK010426 72391 3.390117813 0.000240732
Aspartate-beta-hydroxylase Asph AK016622 74438 3.381429604 0.002146242
Olfactory receptor 71 Olfr71 NM_019486 56015 3.330027109 0.000901758
4921508M14Rik RIKEN cDNA 4921508M14 gene 4921508M14Rik AK014845 70844 3.298529884 1.04069E−05
Zinc ﬁnger, HIT domain containing 2 Znhit2 NM_013859 29805 3.271809765 6.88168E−05
Junctophilin 3 Jph3 NM_020605 57340 3.24968487 4.60595E−05
Erythropoietin receptor Epor NM_010149 13857 3.231908246 0.000478165
Ts translation elongation factor, mitochondrial Tsfm AK012240 66399 3.206533785 0.002855469
RecQ protein-like Recql NM_023042 19691 3.206053436 0.0043986
Kelch repeat and BTB (POZ) domain containing 11 Kbtbd11 AK015509 74901 3.196040676 0.005729286
RNA binding motif protein 3 Rbm3 NM_016809 19652 3.185830609 0.005382789
Homeo box A1 Hoxa1 NM_010449 15394 3.116642156 0.005732354
Guanylate cyclase 2e Gucy2e NM_008192 14919 3.082595924 0.00695869
Abhydrolase domain containing 2 Abhd2 NM_018811 54608 3.078994713 0.000276828
Interleukin 1 receptor accessory protein Il1rap NM_008364 16180 3.073433084 0.00157315
Zinc ﬁnger protein 422 Zfp422 BC018339 67255 3.066355405 0.001295152
Sphingosine-1-phosphate phosphatase 1 Sgpp1 NM_030750 81535 3.052519119 0.00075556
MAP kinase-activated protein kinase 5 Mapkapk5 NM_010765 17165 3.031791019 0.001771526
Arginyl aminopeptidase (aminopeptidase B) Rnpep NM_007921 13710 3.007055167 0.000817323
Table 6
Correlation of array and real-time PCR data.
Condition/gene Array fold change RT-PCR fold change
1 wk SPARC-null/Tbrg4 2.21 1.73
1 mo SPARC-null/Hyal2 0.30 0.45
3 mo SPARC-null/Xpo5 2.14 3.26
1 wk wild-type/Epha4 3.23 1.94
1 wk wild-type/CD68 2.24 3.4
1 wk wild-type/Iqce 5.26 2.28
3 mo wild-type/Iqce 2.27 2.86
108 M.A. Pershouse et al. / Genomics 94 (2009) 101–109Carlsbad CA). The resulting RNA was puriﬁed using the RNeasy kit
(Qiagen, Valencia, CA) and subsequently treated with DNAse
(Qiagen).
Gene expression analysis
For microarray analysis, reverse transcription and cDNA labeling
were performed using 8 μg of total RNA according to the Superscript
Plus Direct cDNA Labeling Kit (Invitrogen). Labeling efﬁciency was
determined using a NanoDrop Spectrophotometer (NanoDrop
Table 7
Primers used for real-time PCR.
Gene Left primer Right primer UPL probe
Iqce tacctgacagaagccgtgag tgtagacggaagtcccagaga 46
Epha4 aggtgtctgactttggcatgt cagtccaccggataggaatc 88
CD68 gacacttcgggccatgtt gaggaggaccaggccaat 34
Tbrg4 cactcatgaaccacctggaa ccagcgtcactagcaccttc 1
Hyal2 ttggttggtaccaggatgg cctggtagcagctcaggaac 81
Xpo5 cgtcagacattttggccttc catgctgttccatcgaaactt 1
109M.A. Pershouse et al. / Genomics 94 (2009) 101–109Technologies, Wilmington, DE). Labeled cDNA was hybridized over-
night at 42 °C to in-house arrays of oligonucleotides spotted on
epoxysilane coated microscope slides (Erie Scientiﬁc, Thermo Fisher
Scientiﬁc, Waltham, MA). The oligonucleotide set was produced by
MWG Biotech, Inc. (Cork, Ireland), and is composed of 50-base oligos
speciﬁc to 9853 unique mouse genes. Almost all genes have a known
function or clearly deﬁned protein domains. Hybridized arrays were
scanned and analyzed using an Axon GenePix 4000B microarray
scanner (Molecular Devices, Sunnyvale, CA) and Axon GenePix Pro 5.1
software (Molecular Devices). Normalization and ﬂagging was
performed using an R script courtesy of Dr. Terry Speed, University
of California-Berkeley. Replicate analyses and comparisons were
performed using a combination of custom PHP/MySQL programs
and standard Excel spreadsheets. Further analyses were performed
using GoMiner (NCBI), and PathwayStudio (Ariadne Genomics,
Rockville, MD).
For quantitative RT-PCR analysis, a starting amount of 500 ng total
RNA was reverse transcribed using the Transcriptor First Strand cDNA
Synthesis Kit (Roche, Indianapolis, IN) for each time point and
condition. Labeled probes and primer sets for each gene were
designed using the Universal ProbeLibrary system (Roche) and are
listed in Table 7. Real-time PCR reactions were performed on a Bio-Rad
iQ5 instrument (Hercules, CA). The PCR program utilized was: one
cycle of 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and
60 °C for 1 min. Resulting data were normalized to a β-actin control
using the ΔΔCt method.
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